Kevin Robinson | Editor

Articles and archive:

Active Nutrition | Analysis | Cell & Gene Therapy | Containment | Contamination Control | Digital | Distribution | Dosage Forms | Drug Delivery | Finance | Food | Hi Tech Manufacturing | Ingredients | Logistics | Manufacturing | Marketing | Media | Medical Devices | Packaging | Pharma 5.0 | Pharmaceutical | Regulatory | Research & Development | Sustainability

Dr Kevin Robinson is a former molecular biologist turned writer, publishing executive and editor with extensive media experience in the life science, pharmaceutical and nutraceutical sectors

Kevin Robinson

Related content

You need to be a subscriber to read this article.
Click here to find out more.
Cell & Gene Therapy
When the raw material is human: why cell therapy manufacturing breaks the traditional GMP model

When the raw material is human: why cell therapy manufacturing breaks the traditional GMP model

Cell therapy manufacturing challenges the core assumptions of pharmaceutical production; as such, the operational question for manufacturers is whether simply layering existing regulatory frameworks together is enough
Regulatory
From recipes to assays: the historical development of analysis in the British Pharmacopoeia

From recipes to assays: the historical development of analysis in the British Pharmacopoeia

This article traces how the British Pharmacopoeia moved from a compounding manual towards a system of analytical standards. It argues that the change was gradual rather than sudden, with 1914 and 1932 marking especially important stages in the move from preparation instructions to identity, purity and assay requirements
Manufacturing
From fermentation to high containment: Indena’s integrated European platform for HPAPIs and ADC payloads

From fermentation to high containment: Indena’s integrated European platform for HPAPIs and ADC payloads

Indena combines fermentation, botanical sourcing, high-containment processing and GMP scale-up expertise to help sponsors reduce hand‑offs in complex HPAPI and ADC payload supply chains
You need to be a subscriber to read this article.
Click here to find out more.
Cell & Gene Therapy
Cell and gene therapy sector gains fresh backing as suppliers scale-up capacity

Cell and gene therapy sector gains fresh backing as suppliers scale-up capacity

The UK's cell and gene therapy (CGT) supply chain has seen a flurry of activity this week, including a fresh funding round for a Cambridge reagents specialist, a new platform partnership in antibody discovery and expanded sequencing capacity from a genomics diagnostics provider.
Research & Development
From drug substance to drug product: why integration matters in modern pharmaceutical development

From drug substance to drug product: why integration matters in modern pharmaceutical development

Pharmaceutical development is becoming increasingly complex. More challenging molecules, compressed timelines, evolving regulatory expectations and the need for resilient supply chains are placing greater pressure on development and manufacturing teams to make the right decisions earlier
Ingredients
Exceptional excipients enabled with expertise

Exceptional excipients enabled with expertise

Growing regulatory expectations, increasing pressure to secure resilient regional supply chains and the need for more efficient manufacturing are reshaping how medicines are developed and produced
Drug Delivery
Sachets: where patient convenience meets manufacturing precision

Sachets: where patient convenience meets manufacturing precision

For pharmaceutical and nutraceutical developers, a dosage form is more than a delivery decision. It shapes the patient experience, influences manufacturing efficiency and can determine whether a formulation performs as intended
Manufacturing
Beyond specialisation: why integrated CDMO capabilities matter for next-gen therapies

Beyond specialisation: why integrated CDMO capabilities matter for next-gen therapies

Complex therapies require CDMO partners with co‑ordinated scientific, analytical, manufacturing and operational expertise to reduce development risk
Packaging
Schreiner MediPharm develops multifunctional label for SHL Medical’s Quanta Pen

Schreiner MediPharm develops multifunctional label for SHL Medical’s Quanta Pen

The global market for weight management drugs is seeing dynamic growth and increases the demand for powerful self-injection systems
Research & Development
Akiram and ITM sign supply agreement to develop AKIR001 to treat solid tumours

Akiram and ITM sign supply agreement to develop AKIR001 to treat solid tumours

AKIR001 is a targeted antibody-radionuclide conjugate designed to deliver radiation directly to CD44v6-expressing solid tumours, with potential to become a first-in-class therapy
Research & Development
Lupin advances speciality pipeline with FDA approval and European partnership

Lupin advances speciality pipeline with FDA approval and European partnership

Lupin has recently announced two significant developments, reinforcing its momentum in both the US generics market and its global speciality care strategy
Analysis
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies

MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies

The launch comes as base editing advances toward the clinic and regulators place greater emphasis on sensitive, orthogonal approaches to genome safety